Sanofi (SNW MU) stock market data APIs
€79.5024
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Sanofi Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for SNW.MU.
Prev. Close
79.5024
Open
79.5024
High
79.5024
Low
79.5024
52 wk Range
78.29-105.9523
Market Cap
108 619 M
EPS
1.79
Dividends (Yield)
0.0361
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sanofi data using free add-ons & libraries
Get Sanofi Fundamental Data
Sanofi Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 1.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi News
New
Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of best affordable biotech stocks to invest in now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on September 8 the results evaluating �...
Lysosomal Storage Disease Treatment Market Analysis Report 2025-2034: Breakthroughs in Enzyme & Gene Therapies, Early Diagnosis Drive Demand
Company Logo Lysosomal Storage Disease Treatment MarketLysosomal Storage Disease Treatment Market Dublin, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The "Lysosomal Storage Disease Treatment Market Opportuni...
Sanofi (SNY) Fell on Tariff Uncertainty
Ariel Investments, an investment management company, released its “Ariel Global Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter marked a ...
AstraZeneca says Fasenra misses main goal in COPD trial
`` Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary diseas...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
